APA (7th ed.) Citation

Mesa, R. A., Schaap, N., Vannucchi, A. M., Kiladjian, J., Passamonti, F., Zweegman, S., . . . Harrison, C. N. (2021). Patient-reported Effects of Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2, on Myelofibrosis-related Symptoms and Health-related Quality of Life in the Randomized, Placebo-controlled, Phase III JAKARTA Trial. Wiley.

Chicago Style (17th ed.) Citation

Mesa, Ruben A., et al. Patient-reported Effects of Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2, on Myelofibrosis-related Symptoms and Health-related Quality of Life in the Randomized, Placebo-controlled, Phase III JAKARTA Trial. Wiley, 2021.

MLA (9th ed.) Citation

Mesa, Ruben A., et al. Patient-reported Effects of Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2, on Myelofibrosis-related Symptoms and Health-related Quality of Life in the Randomized, Placebo-controlled, Phase III JAKARTA Trial. Wiley, 2021.